Optimization of the central heterocycle of α-ketoheterocycle inhibitors of fatty acid amide hydrolase

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4392-4403

  Garfunkle, Joie ^a   Ezzili, Cyrine ^a   Rayl, Thomas J ^a   Hochstatter, Dustin G ^a   Hwang, Inkyu ^a   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIAZINE DERIVATIVE; 1,2,4 OXADIAZOLE DERIVATIVE; 1,3,4 OXADIAZOLE DERIVATIVE; 1,3,4 THIADIAZOLE DERIVATIVE; FATTY ACID AMIDASE INHIBITOR; GABAPENTIN; IBUPROFEN; MORPHINE; OXAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG BINDING SITE; DRUG INHIBITION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HOT PLATE TEST; ISOMER; MOUSE; NEUROPATHIC PAIN; NOCICEPTIVE STIMULATION; NONHUMAN; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; TAIL FLICK TEST;

AMIDOHYDROLASES; ANIMALS; AZOLES; CERCOPITHECUS AETHIOPS; COS CELLS; ELECTRONS; ENZYME INHIBITORS; ESCHERICHIA COLI; HETEROCYCLIC COMPOUNDS; HUMANS; ISOMERISM; METHYLATION; MOLECULAR STRUCTURE; OXAZOLES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 49449114646     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800136b     Document Type: Article

References (98)

1. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular Characterization of an Enzyme that Degrades Neuromodulatory Fatty Acid Amides. Nature 1996, 384, 83-87.
2. Giang, D. K.; Cravatt, B. F. Molecular Characterization of Human and Mouse Fatty Acid Amide Hydrolases. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2238-2242.
3. Patricelli, M. P.; Cravatt, B. F. Proteins Regulating the Biosynthesis and Inactivation of Neuromodulatory Fatty Acid Amides. Vit. Hormones 2001, 62, 95-131.
4. Egertova, M.; Cravatt, B. F.; Elphick, M. R. Comparative Analysis of Fatty Acid Amide Hydrolase and CB1 Cannabinoid Receptor Expression in the Mouse Brain: Evidence of a Widespread Role for Fatty Acid Amide Hydrolase in Regulation of Endocannabinoid Signaling. Neuroscience 2003, 119, 481-496.
5. Boger, D. L.; Fecik, R. A.; Patterson, J. E.; Miyauchi, H.; Patricelli, M. P.; Cravatt, B. F. Fatty Acid Amide Hydrolase Substrate Specificity. Bioorg. Med. Chem. Lett. 2000, 10, 2613-2616.
6. Lang, W.; Qin, C.; Lin, S.; Khanolkar, A. D.; Goutopoulos, A.; Fan, P.; Abouzid, K.; Meng, Z.; Biegel, D.; Makriyannis, A. Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase. J. Med. Chem. 1999, 42, 896-902.
7. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. Science 1992, 258, 1946-1949.
8. Martin, B. R.; Mechoulam, R.; Razdan, R. K. Discovery and Characterization of Endogenous Cannabinoids. Life Sci. 1999, 65, 573-595.
9. Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Melck, D.; Martin, B. R. Cannabimimetic Fatty Acid Derivatives: The Anandamide Family and Other "Endocannabinoids". Curr. Med. Chem. 1999, 6, 721-744.
10. Schmid, H. H. O.; Schmid, P. C.; Natarajan, V. N-Acylated Glycerophospholipids and Their Derivatives. Prog. Lipid Res. 1990, 29, 1-43.
11. Boger, D. L.; Henriksen, S. J.; Cravatt, B. F. Oleamide: An Endogenous Sleep-Inducing Lipid and Prototypical Member of a New Class of Lipid Signaling Molecules. Curr. Pharm. Des. 1998, 4, 303-314.
12. Cravatt, B. F.; Lerner, R. A.; Boger, D. L. Structure Determination of an Endogenous Sleep-Inducing Lipid cis-9-Octadecenamide (Oleamide): A Synthetic Approach to the Chemical Analysis of Trace Quantitites of a Natural Product. J. Am. Chem. Soc. 1996, 118, 580-590.
13. Cravatt, B. F.; Prospero-Garcia, O.; Suizdak, G.; Gilula, N. B.; Henriksen, S. J.; Boger, D. L.; Lerner, R. A. Chemical Characterization of a Family of Brain Lipids that Induce Sleep. Science 1995, 268, 1506-1509.
14. Patricelli, M. P.; Cravatt, B. F. Fatty Acid Amide Hydrolase Competitively Degrades Bioactive Amides and Esters Through a Nonconventional Catalytic Mechanism. Biochemistry 1999, 38, 14125-14130.
15. Patricelli, M. P.; Cravatt, B. F. Clarifying the Catalytic Roles of Conserved Residues in the Amidase Signature Family. J. Biol. Chem. 2000, 275, 19177-19184.
16. Patricelli, M. P.; Lovato, M. A.; Cravatt, B. F. Chemical and Mutagenic Investigations of Fatty Acid Amide Hydrolase: Evidence for a Family of Serine Hydrolases with Distinct Catalytic Properties. Biochemistry 1999, 38, 9804-9812.
17. Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural Adaptations in a Membrane Enzyme that Terminates Endocannabinoid Signaling. Science 2002, 298, 1793-1796.
18. Fowler, C. J.; Jonsson, K.-D.; Tiger, G. Fatty Acid Amide Hydrolase: Biochemistry, Pharmacology, and Therapeutic Possibilities for an Enzyme Hydrolyzing Anandamide, 2-Arachidonoylglycerol, Palmitoylethanolamide, and Oleamide. Biochem. Pharmacol. 2001, 62, 517-526.
19. Cravatt, B. F.; Lichtman, A. H. Fatty Acid Amide Hydrolase: An Emerging Therapeutic Target in the Endocannabinoid System. Curr. Opin. Chem. Biol. 2003, 7, 469-475.
20. Lambert, D. M.; Fowler, C. J. The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications. J. Med. Chem. 2005, 48, 5059-5087.
21. Cravatt, B. F.; Demarest, K.; Patricelli, M. P.; Bracey, M. H.; Giang, D. K.; Martin, B. R.; Lichtman, A. H. Supersensitivity to Anandamide and Enhanced Endogenous Cannabinoid Signaling in Mice Lacking Fatty Acid Amide Hydrolase. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 9371-9376.
22. Lichtman, A. H.; Shelton, C. C.; Advani, T.; Cravatt, B. F. Mice Lacking Fatty Acid Amide Hydrolase Exhibit a Cannabinoid Receptor-Mediated Phenotypic Hypoalgesia. Pain 2004, 109, 319-327.
23. Cravatt, B. F.; Saghatelian, A.; Hawkins, E. G.; Clement, A. B.; Bracey, M. H.; Lichtman, A. H. Functional Disassociation of the Central and Peripheral Fatty Acid Amide Signaling Systems. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 10821-10826.
24. Karsak, M.; Gaffal, E.; Date, R.; Wang-Eckhardt, L.; Rehnelt, J.; Petrosino, S.; Starowicz, K.; Steuder, R.; Schlicker, E.; Cravatt, B. F.; Mechoulam, R.; Buettner, R.; Werner, S.; Di Marzo, V.; Tueting, T.; Zimmer, A. Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System. Science 2007, 316, 1494-1497.
25. (a) Huitrón-Reséndiz, S.; Gombart, L.; Cravatt, B. F.; Henriksen, S. J. Effect of Oleamide on Sleep and Its Relationship to Blood Pressure, Body Temperature, and Locomotor Activity in Rats. Exp. Neurol. 2001, 172, 235-243.
26. (b) Huitrón-Reséndiz, S.; Sanchez-Alavez, M.; Wills, D. N.; Cravatt, B. F.; Henriksen, S. J. Characterization of the Sleep-Wake Patterns in Mice Lacking Fatty Acid Amide Hydrolase. Sleep 2004, 27, 857-865.
27. Clement, A. B.; Hawkins, E. G.; Lichtman, A. H.; Cravatt, B. F. Increased Seizure Susceptibility and Proconvulsant Activity of Anandamide in Mice Lacking Fatty Acid Amide Hydrolase. J. Neurosci. 2003, 23, 3916-3923.
28. Patricelli, M. P.; Patterson, J. P.; Boger, D. L.; Cravatt, B. F. An Endogenous Sleep-Inducing Compound is a Novel Competitive Inhibitor of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 1998, 8, 613-618.
29. Koutek, B.; Prestwich, G. D.; Howlett, A. C.; Chin, S. A.; Salehani, D.; Akhavan, N.; Deutsch, D. G. Inhibitors of Arachidonoyl Ethanolamide Hydrolysis. J. Biol. Chem. 1994, 269, 22937-22940.
30. Patterson, J. E.; Ollmann, I. R.; Cravatt, B. F.; Boger, D. L.; Wong, C.-H.; Lerner, R. A. Inhibition of Oleamide Hydrolase Catalyzed Hydrolysis of the Endogenous Sleep-Inducing Lipid cis-9-Octadecenamide. J. Am. Chem. Soc. 1996, 118, 5938-5945.
31. Boger, D. L.; Sato, H.; Lerner, A. E.; Austin, B. J.; Patterson, J. E.; Patricelli, M. P.; Cravatt, B. F. Trifluoromethyl Ketone Inhibitors of Fatty Acid Amide Hydrolase: A Probe of Structural and Conformational Features Contributing to Inhibition. Bioorg. Med. Chem. Lett. 1999, 9, 265-270.
32. Leung, D.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Discovering Potent and Selective Reversible Inhibitors of Enzymes in Complex Proteomes. Nat. Biotechnol. 2003, 21, 687-691.
33. De Petrocellis, L.; Melck, D.; Ueda, N.; Maurelli, S.; Kurahashi, Y.; Yamamoto, S.; Marino, G.; Di Marzo, V. Novel Inhibitors of Brain, Neuronal, and Basophilic Anandamide Amidohydrolase. Biochem. Biophys. Res. Commun. 1997, 231, 82-88.
34. Deutsch, D. G.; Omeir, R.; Arreaza, G.; Salehani, D.; Prestwich, G. D.; Huang, Z.; Howlett, A. Methyl Arachidonyl Fluorophosphonate: A Potent Irreversible Inhibitor of Anandamide Amidase. Biochem. Pharmacol. 1997, 53, 255-260.
35. Deutsch, D. G.; Lin, S.; Hill, W. A. G.; Morse, K. L.; Salehani, D.; Arreaza, G.; Omeir, R. L.; Makriyannis, A. Fatty Acid Sulfonyl Fluorides Inhibit Anandamide Metabolism and Bind to the Cannabinoid Receptor. Biochem. Biophys. Res. Commun. 1997, 231, 217-221.
36. Edgemond, W. S.; Greenberg, M. J.; McGinley, P. J.; Muthians, S.; Campbell, W. B.; Hillard, C. J. Synthesis and Characterization of Diazomethylarachidonyl Ketone: An Irreversible Inhibitor of N- Arachidonylethanolamine Amidohydrolase. J. Pharmacol. Exp. Ther. 1998, 286, 184-190.
37. Fernando, S. R.; Pertwee, R. G. Evidence that Methyl Arachidonyl Fluorophosphonate is an Irreversible Cannabinoid Receptor Antagonist. Br. J. Pharmacol. 1997, 121, 1716-1720.
38. Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Boger, D. L. Heterocyclic Sulfoxide and Sulfone Inhibitors of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 2005, 15, 103-106.
39. (a) Kathuria, S.; Gaetani, S.; Fegley, D.; Valino, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of Anxiety Through Blockade of Anandamide Hydrolysis. Nat. Med. 2003, 9, 76-81.
40. (b) Gobbi, G.; Bambico, F. R.; Mangieri, R.; Bortolato, M.; Campolongo, P.; Solinas, M.; Cassano, T.; Morgese, M. G.; Debonnel, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Mor, M.; Trezza, V.; Goldberg, S. R.; Cuomo, V.; Piomelli, D. Antidepressant-Like Activity and Modulation of Brain Monaminergic Transmission by Blockage of Anandamide Hydrolase. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 18620-18625.
41. Jayamanne, A.; Greenwood, R.; Mitchell, V. A.; Asian, S.; Piomelli, D.; Vaughan, C. W. Actions of the FAAH Inhibitor URB597 in Neuropathic and Inflammatory Chronic Pain Models. Br. J. Pharmacol. 2006, 147, 281-288.
42. Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic Acid 3′- or 4′-Substituted Biphenyl-3-yl Esters as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships, and Molecular Modeling Studies. J. Med. Chem. 2004, 47, 4998-5008.
43. (a) Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, Synthesis, and Structure - Activity Relationships of Alkylcarbamic Acid Aryl Esters, a New Class of Fatty Acid Amide Hydrolase Inhibitors. J. Med. Chem. 2003, 46, 2352-2360.
44. (b) Tarzia, G.; Duranti, A.; Gatti, G.; Piersanti, G.; Tontini, A.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Mor, M.; Kathuria, S.; Piomelli, D. Synthesis and Structure - Activity Relationships of FAAH Inhibitors: Cyclohexylcarbamic Acid Biphenyl Esters with Chemical Modulation at the Proximal Phenyl Ring. Chem. Med. Chem. 2006, 1, 130-139.
45. Ahn, K.; Johnson, D. S.; Fitzgerald, L. R.; Liimatta, M.; Arendse, A.; Stevenson, T.; Lund, E. T.; Nugent, R. A.; Normanbhoy, T.; Alexander, J. P.; Cravatt, B. F. A Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity. Biochemistry 2007, 46, 13019-13030.
46. (a) Abouab-Dellah, A.; Burnier, P.; Hoornaert, C.; Jeunesse, J.; Puech, F. (Sanofi). Derivatives of Piperidinyl-and Piperazinyl-alkyl Carbamates, Preparation Methods and Application in Therapeutics. Patent WO 2004/099176, 2004.
47. (b) Abouab-Dellah, A.; Almario, G. A.; Froissant, J.; Hoornaert, C. (Sanofi). Aryloxyalkylcarbamate Derivatives, Including Piperidine Carbamates, Their Preparation and Use as Fatty Acid Amide Hydrolase (FAAH) Inhibitors for Treating FAAH-Related Pathologies. Patent WO 2005/077898, 2005.
48. (c) Abouab-Dellah, A.; Almario, G. A.; Hoornaert, C.; Li, A. T. (Sanofi). 1-Piperazine and 1-Homopiperazine Derivatives, Their Preparation and Use as Fatty Acid Amide Hydrolase (FAAH) Inhibitors for Treating FAAH-Related Pathologies. Patent WO 2005/070910, 2005.
49. (d) Abouab-Dellah, A.; Almario, G. A.; Hoornaert, C.; Li, A. T. (Sanofi). Alkyl(homo)piperazine-carboxylate Derivatives, Their Preparation and Use as Fatty Acid Amide Hydrolase (FAAH) Inhibitors for Treating FAAH-Related Pathologies. Patent WO 2007/027141, 2007.
50. (a) Sit, S.-Y.; Xie, K.; Deng, H. (Bristol-Myers Squibb). Preparation of (Hetero)aryl Carbamates and Oximes as Fatty Acid Amide Hydrolase Inhibitors. Patent WO2003/06589, 2003.
51. (b) Sit, S.-Y.; Xie, K. (Bristol-Myers Squibb). Preparation of Bis Arylimidazolyl Fatty Acid Amide Hydrolase Inhibitors for Treatment of Pain. Patent WO 2002/0875692002.
52. (c) Sit, S. Y.; Conway, C.; Bertekap, R.; Xie, K.; Bourin, C.; Burris, K.; Deng, H. Novel Inhibitors of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 2007, 17, 3287-3291.
53. (a) Apodaca, R.; Breitenbucher, J. G.; Pattabiraman, K.; Seierstad, M.; Xiao, W. (J&J). Piperazinvl and Piperidinyl Ureas as Modulators of Fatty Acid Amide Hydrolase. U.S. Patent 2006/01731842006.
54. (b) Apodaca, R.; Breitenbucher, J. G.; Pattabiraman, K.; Seierstad, M.; Xiao, W. (J&J). Preparation of Thiadiazolylpiperazine Carboxamides as Modulators of Fatty Acid Amide Hydrolase (FAAH). U.S. Patent 2007/0047412007.
55. (a) Matsumoto, T.; Kori, M.; Miyazaki, J.; Kiyota, Y. (Takeda). Preparation of Piperidinecarboxamides and Piperazinecarboxamides as Fatty Acid Amide Hydrolase (FAAH) Inhibitors. Patent WO 2006054652, 2006.
56. (b) Matsumoto, T.; Kori, M.; Kouno, M. (Takeda). Preparation of Piperazine-1-carboxamide Derivatives as Brain/Neuronal Cell-protecting Agents, and Therapeutic Agents for Sleep Disorder. Patent WO 2007020888, 2007.
57. Ishii, T.; Sugane, T.; Maeda, J.; Narazaki, F.; Kakefuda, A.; Sato, K.; Takahashi, T.; Kanayama, T.; Saitoh, C.; Suzuki, J.; Kanai, C. (Astellas). Preparation of Pyridyl Nonaromatic Nitrogenated Heterocyclic-1-carboxylate Ester Derivatives as FAAH Inhibitors, Patent WO 2006/088075, 2006.
58. (a) Moore, S. A.; Nomikos, G. G.; Dickason-Chesterfield, A. K.; Sohober, D. A.; Schaus, J. M.; Ying, B. P.; Xu, Y. C.; Phebus, L.; Simmons, R. M.; Li, D.; Iyengar, S.; Felder, C. C. Identification of a High-Affinity Binding Site Involved in the Transport of Endocannabinoids (LY2183240). Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17852-17857.
59. Alexander, J. P.; Cravatt, B. F. The Putative Endocannabinoid Transport Blocker LY2183240 is a Potent Inhibitor of FAAH and Several Other Brain Serine Hydrolases. J. Am. Chem. Soc. 2006, 128, 9699-9704.
60. Alexander, J. P.; Cravatt, B. F. Mechanism of Carbamate Inactivation of FAAH: Implications for the Design of Covalent Inhibitors and In Vivo Functional Probes for Enzymes. Chem. Biol. 2005, 12, 1179-1187.
61. Zhang, D.; Saraf, A.; Kolasa, T.; Bhatia, P.; Zheng, G. Z.; Patel, M.; Lannoye, G. S.; Richardson, P.; Stewart, A.; Rogers, J. C.; Brioni, J. D.; Surowy, C. S. Fatty Acid Amide Hydrolase Inhibitors Display Broad Selectivity and Inhibit Multiple Carboxylesterases as Off-Targets. Neuropharmacol. 2007, 52, 1095-1105.
62. Boger, D. L.; Sato, H.; Lerner, A. E.; Hedrick, M. P.; Fecik, R. A.; Miyauchi, H.; Wilkie, G. D.; Austin, B. J.; Patricelli, M. P.; Cravatt, B. F. Exceptionally Potent Inhibitors of Fatty Acid Amide Hydrolase: The Enzyme Responsible for Degradation of Endogenous Oleamide and Anandamide. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5044-5049.
63. Boger, D. L.; Miyauchi, H.; Hedrick, M. P. α-Keto Heterocycle Inhibitors of Fatty Acid Amide Hydrolase: Carbonyl Group Modification and α-Substitution. Bioorg. Med. Chem. Lett. 2001, 11, 1517-1520.
64. Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimaráes, C. R. W.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a Potent, Selective, and Efficacious Class of Reversible α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase as Analgesics. J. Med. Chem. 2005, 48, 1849-1856.
65. Leung, D.; Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Discovery of an Exceptionally Potent and Selective Class of Fatty Acid Amide Hydrolase Inhibitors Enlisting Proteome-Wide Selectivity Screening: Concurrent Optimization of Enzyme Inhibitor Potency and Selectivity. Bioorg. Med. Chem. Lett. 2005, 15, 1423-1428.
66. Romero, F. A.; Hwang, I.; Boger, D. L. Delineation of a Fundamental α-Ketoheterocycle Substituent Effect for Use in the Design of Enzyme Inhibitors. J. Am. Chem. Soc. 2006, 68, 14004-14005.
67. Romero, F. A.; Du, W.; Hwang, I.; Rayl, T. J.; Kimball, F. S.; Leung, D.; Hoover, H. S.; Apodaca, R. L.; Breitenbucher, B. J.; Cravatt, B. F.; Boger, D. L. Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase. J. Med. Chem. 2007, 50, 1058-1068.
68. Hardouin, C.; Kelso, M. J.; Romero, F. A.; Rayl, T. J.; Leung, D.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Structure-Activity Relationships of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase. J. Med. Chem. 2007, 50, 3359-3368.
69. Kimball, F. S.; Romero, F. A.; Ezzili, C.; Garfunkle, J.; Rayl, T. J.; Hochsttater, D. G.; Hwang, I.; Boger, D. L. Optimization of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase. J. Med. Chem. 2008, 51, 937-947.
70. (a) Lichtman, A. H.; Leung, D.; Shelton, C. C.; Saghatelian, A.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Reversible Inhibitors of Fatty Acid Amide Hydrolase that Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity. J. Pharmacol. Exp. Ther. 2004, 311, 441-448.
71. (b) Chang, L.; Luo, L.; Palmer, J. A.; Sutton, S.; Wilson, S. J.; Barbier, A. J.; Breitenbucher, J. G.; Chaplan, S. R.; Webb, M. Inhibition of Fatty Acid Amide Hydrolase Produces Analgesia by Multiple Mechanisms. Br. J. Pharmacol. 2006, 148, 102-113.
72. (a) Muccioli, G. G.; Fazio, N.; Scriba, G. K. E.; Poppitz, W.; Cannata, F.; Poupaert, J. H.; Wouters, J.; Lambert, D. M. Substituted 2-Thioxoimidazolidin-4-ones and Imidazolidine-2,4-diones as Fatty Acid Amide Hydrolase Inhibitors Templates. J. Med. Chem. 2006, 49, 417-425.
73. (b) Saario, S. M.; Poso, A.; Juvonen, R. O.; Jarvinen, T.; Salo-Ahen, O. M. H. Fatty Acid Amide Hydrolase Inhibitors from Virtual Screening of the Endocannabinoid System. J. Med. Chem. 2006, 49, 4650-4656.
74. (c) Myllymaki, M. J.; Saario, S. M.; Kataja, A. O.; Castillo-Melendez, J. A.; Navalainen, T.; Juvonen, R. O.; Jarvinen, T.; Koskinen, A. M. P. Design, Synthesis, and In Vitro Evaluation of Carbamate Derivatives of 2-Benzoxazolyl- and 2-Benzothiazolyl-(3-hydroxyphenyl)-methanones as Novel Fatty Acid Amide Hydrolase Inhibitors. J. Med. Chem. 2007, 50, 4236-4242.
75. Rawal, V. H.; Rao, J. A.; Cava, M. P. A Convenient Synthesis of t-Butyldimethylsilyl Protected Cyanohydrins. Tetrahedron Lett. 1985, 26, 4275-4278.
76. (a) Kauffman, Th. Reactions of Sodium Hydrazide with Organic Compounds. Angew. Chem., Int. Ed. 1964, 3, 342-353.
77. (b) Garg, N. K.; Stoltz, B. M. Synthesis of Bis(indole)-1,2,4- triazinones. Tetrahedron Lett. 2005, 46, 1997-2000.
78. (c) Li, J. H.; Snyder, J. K. Pyrrole as a Dienophile in Intramolecular Inverse Electron-Demand Diels - Alder Reactions with 1,2,4-Triazines. J. Org. Chem. 1993, 58, 516-519.
79. (a) Walker, D.; Hiebert, J. D. 2,3-Dichloro-5,6-dicyanobenzoquinone and Its Reactions. Chem. Rev. 1967, 67, 153-195.
80. (b) Bruché, L.; Zecchi, G. The Intramolecular Nitrile Imine Cycloaddition Route to Pyrazolo[1,5-a][1,4]benzodiazepines. Tetrahedron 1989, 45, 7427-7432.
81. Dess, D. B.; Martin, J. C. A Useful 12-I-5 Triacetoxyperiodinane (the Dess - Martin Periodinane) for the Selective Oxidation of Primary or Secondary Alcohols and a Variety of Related 12-I-5 Species. J. Am. Chem. Soc. 1991, 113, 7277-7287.
82. Demko, Z. P.; Sharpless, K. B. An Expedient Route to the Tetrazole Analogues of α-Amino Acids. Org. Lett. 2002, 4, 2525-2527.
83. (a) Ley, S. V.; Thomas, A. W. Modern Synthetic Methods for Copper-Mediated C(aryl)-O, C(aryl)-N, and C(aryl)-S Bond Formation. Angew. Chem., Int. Ed. 2003, 42, 5400-5449.
84. (b) Christau, H.-J.; Cellier, P. P.; Spindler, J.-F.; Taillefer, M. Highly Efficient and Mild Copper-Catalyzed N- and C-Arylations with Aryl Bromides and Iodides. Chem. - Eur. J. 2004, 10, 5607-5622.
85. (c) Antilla, J. C.; Baskin, J. M.; Barder, T. E.; Buchwald, S. L. Copper-Diamine-Catalyzed N-Arylation of Pyrroles, Pyrazoles, Indazoles, Imidazoles, and Triazoles. J. Org. Chem. 2004, 69, 5578-5587.
86. (a) Beletskaya, I. P.; Davydov, D. V.; Gorovoy, M. S. Palladium-and Copper-Catalyzed Selective Arylation of 5-Aryltetrazoles by Diaryliodonium Salts. Tetrahedron Lett. 2002, 43, 6221-6223.
87. 2. Tetrahedron Lett. 2002, 4, 6217-6219.
88. (c) Carroll, M. A.; Pike, V. W.; Widdowson, D. A. New Synthesis of Diaryliodonium Sulfonates from Arylboronic Acids. Tetrahedron Lett. 2000, 41, 5393-5396.
89. Stangeland, E. L.; Sammakia, T. Use of Thiazoles in the Halogen Dance Reaction: Application to the Total Synthesis of WS75624 B. J. Org. Chem. 2004, 69, 2381-2385.
90. (a) For a review, see Iddon, B. Synthesis and Reactions of Lithiated Monocyclic Azoles Containing Two or More Hetero-Atoms. Part V: Isothiazoles and Thiazoles. Heterocycles 1995, 41, 533-593.
91. Farina, V.; Krishnamurthy, V.; Scott, W. J. The Stille Reaction. Org. React. 1997, 50, 1-652.
92. Olsen, A. G.; Dahl, O.; Nielsen, P. E. Synthesis and Evaluation of a Conformationally Constrained Pyridazinone PNA-monomer for Recognition of Thymine in Triple-Helix Structures. Bioorg. Med. Chem. Lett. 2004, 14, 1551-1554.
93. Patricelli, M. P.; Lashuel, H. A.; Giang, D. K.; Kelly, J. W.; Cravatt, B. F. Comparative Characterization of a Wild Type and Transmembrane Domain-Deleted Fatty Acid Amide Hydrolase: Identification of the Transmembrane Domain as a Site for Oligomerization. Biochemistry 1998, 37, 15177-15187.
94. (a) Guimaráes, C. R. W.; Boger, D. L.; Jorgensen, W. L. Elucidation of Fatty Acid Amide Hydrolase Inhibition by Potent α-Ketoheterocycle Derivatives from Monte Carlo Simulations. J. Am. Chem. Soc. 2005, 127, 17377-17384.
95. (b) Tubert-Brohman, I.; Acevedo, O.; Jorgensen, W. L. Elucidation of Hydrolysis Mechanisms for Fatty Acid Amide Hydrolase and its Lys142Ala Variant via QMZMM Simulations. J. Am. Chem. Soc. 2006, 128, 16904-16913.
96. (a) Kidd, D.; Liu, Y.; Cravatt, B. F. Profiling Serine Hydrolase Activities in Complex Proteomes. Biochemistry 2001, 40, 4005-4015.
97. (b) Liu, Y.; Patricelli, M. P.; Cravatt, B. F. Activity-Based Protein Profiling: the Serine Hydrolases. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14694-14699.
98. Chiang, K. P.; Niessen, S.; Saghatelian, A.; Cravatt, B. F. An Enzyme that Regulates Ether Lipid Signaling Pathways in Cancer Annotated by Multidimensional Profiling. Chem. Biol. 2006, 13, 1041-1050.